TickerTalks
Browse all tickers →
TickerTalks›$GENB
GEGENB

Generate Biomedicines, Inc.

$GENB·$1.6B·Asset Management·Financial Services
$12.85-0.2%
Mentions · last 7 days
2026-06-02: 5 posts2026-06-03: 14 posts2026-06-04: 32 posts2026-06-05: 25 posts2026-06-06: 9 posts2026-06-07: 4 posts2026-06-08: 16 posts105+18%
Price updated 12h ago·X counts updated 7h ago
GEGENB
Generate Biomedicines, Inc.$GENB
$12.85-0.16%105 posts+18%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $GENB, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-06-08

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Post-IPO drug developer bases near support supported by institutional accumulations.

Generate Biomedicines is coiling as institutional investors accumulate shares following its initial public offering. Speculators are tracking its pipeline progress and presentations at upcoming global healthcare conferences for clinical updates. The stock trades at a premium price-to-sales ratio of 51.7 on limited commercial revenues. First-quarter revenue was $7.2 million, resulting in a negative operating margin of -887.5% and a negative free cash flow yield of -12.4% due to research and development spending.

What to watch: Clinical trial updates and presentation responses from the upcoming medical conferences ahead of the August sixth earnings report.

On the calendar: 2026-08-06 — Q2 2026 earnings

Read the AI verdict + X sentiment for $GENB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Asset Management sits in its cycle right now — and what that implies for $GENB.

Asset Management · Financial Services

Bitcoin treasury strategies and AI-adjacent deal flow are the dual structural frames — ASST follows MicroStrategy's BTC-per-share capital allocation model while BX, APO, and BN deploy alternative capital into AI infrastructure, data center real estate, and private credit. CLARITY Act regulatory clarity accelerates crypto AUM at capital markets firms.

See how Asset Management shapes $GENB

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $GENB's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IAIiShares U.S. Broker-Dealers & Securities Exchanges ETF
-0.0%YTD
+16.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-89.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-7.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-12.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
51.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
38.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
100%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.
Next earningsThu, Aug 6·consensus EPS $-0.48

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.2M—54.7%-887%$-0.54$-84.2M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$31.1M$25.3M – $38.1M-$2.23-$2.39 – -$2.115
FY27$23.7M$4.5M – $39.6M-$2.15-$2.50 – -$1.665
FY28$92.2M$92.2M – $92.2M-$1.73-$2.09 – -$1.364
FY29$22.5M$12.2M – $32.0M-$2.81-$4.34 – -$1.143
FY30$163.2M$88.6M – $231.9M-$2.44-$3.78 – -$0.993

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Know if $GENB is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMar 123
8-KCharter amendmentMar 28-K — Item 5.03: Charter amendment
424B4Prospectus supplement (offering)Feb 27424B4
3New insider — initial holdingsFeb 263
3New insider — initial holdingsFeb 263
3New insider — initial holdingsFeb 263
3New insider — initial holdingsFeb 263
3New insider — initial holdingsFeb 263
+ 23 other (11 3s · 2 13Gs · 2 S-1/As · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developerfool.com·9d agoGenerate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conferenceprnewswire.com·12d agoGenerate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Updateprnewswire.com·33d ago

More in Asset Management

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ASST$SATA$OWL$DXYZ$BN$BX$APO$PS
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport